IL143921A - Compositions for the treatment and prevention of tumor-related disorders, for inhibiting tumor growth and for inhibiting tumor metastasis - Google Patents

Compositions for the treatment and prevention of tumor-related disorders, for inhibiting tumor growth and for inhibiting tumor metastasis

Info

Publication number
IL143921A
IL143921A IL14392198A IL14392198A IL143921A IL 143921 A IL143921 A IL 143921A IL 14392198 A IL14392198 A IL 14392198A IL 14392198 A IL14392198 A IL 14392198A IL 143921 A IL143921 A IL 143921A
Authority
IL
Israel
Prior art keywords
tumor
inhibiting tumor
prevention
compositions
treatment
Prior art date
Application number
IL14392198A
Other languages
English (en)
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of IL143921A publication Critical patent/IL143921A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A47FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47GHOUSEHOLD OR TABLE EQUIPMENT
    • A47G7/00Flower holders or the like
    • A47G7/02Devices for supporting flower-pots or cut flowers
    • A47G7/04Flower tables; Stands or hangers, e.g. baskets, for flowers
    • A47G7/044Hanging flower-pot holders, e.g. mounted on walls, balcony fences or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01GHORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
    • A01G5/00Floral handling
    • A01G5/04Mountings for wreaths, or the like; Racks or holders for flowers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10Sulfides; Sulfoxides; Sulfones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4021-aryl substituted, e.g. piretanide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G09EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09FDISPLAYING; ADVERTISING; SIGNS; LABELS OR NAME-PLATES; SEALS
    • G09F23/00Advertising on or in specific articles, e.g. ashtrays, letter-boxes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Theoretical Computer Science (AREA)
  • Neurology (AREA)
  • Environmental Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL14392198A 1997-12-24 1998-12-21 Compositions for the treatment and prevention of tumor-related disorders, for inhibiting tumor growth and for inhibiting tumor metastasis IL143921A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP35449997 1997-12-24
JP1530698 1998-01-28
JP20490798 1998-07-21
JP26944498 1998-09-24
IL12766498A IL127664A (en) 1997-12-24 1998-12-21 Compositions for the treatment and prevention of cachexia

Publications (1)

Publication Number Publication Date
IL143921A true IL143921A (en) 2003-11-23

Family

ID=27456356

Family Applications (3)

Application Number Title Priority Date Filing Date
IL12766498A IL127664A (en) 1997-12-24 1998-12-21 Compositions for the treatment and prevention of cachexia
IL14392198A IL143921A (en) 1997-12-24 1998-12-21 Compositions for the treatment and prevention of tumor-related disorders, for inhibiting tumor growth and for inhibiting tumor metastasis
IL14392101A IL143921A0 (en) 1997-12-24 2001-06-21 Compositions for the treatment and prevention of tumors and tumor-related disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL12766498A IL127664A (en) 1997-12-24 1998-12-21 Compositions for the treatment and prevention of cachexia

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL14392101A IL143921A0 (en) 1997-12-24 2001-06-21 Compositions for the treatment and prevention of tumors and tumor-related disorders

Country Status (22)

Country Link
US (3) US6887893B1 (xx)
EP (1) EP0927555B1 (xx)
KR (2) KR100432926B1 (xx)
CN (1) CN1149990C (xx)
AR (1) AR012272A1 (xx)
AT (1) ATE527022T1 (xx)
AU (1) AU745865B2 (xx)
BR (1) BR9805544C1 (xx)
CA (1) CA2257010C (xx)
CZ (1) CZ299060B6 (xx)
DK (1) DK0927555T3 (xx)
ES (1) ES2372921T3 (xx)
HK (1) HK1020261A1 (xx)
HU (1) HU227126B1 (xx)
ID (1) ID21529A (xx)
IL (3) IL127664A (xx)
NO (2) NO317568B1 (xx)
NZ (1) NZ333399A (xx)
PL (1) PL193093B1 (xx)
SA (1) SA99191102B1 (xx)
TR (1) TR199802676A3 (xx)
TW (1) TW562675B (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703418B2 (en) * 1991-02-26 2004-03-09 Unimed Pharmaceuticals, Inc. Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection
US20040072889A1 (en) 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
WO2000038730A2 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
JP2003503360A (ja) * 1999-06-24 2003-01-28 ファルマシア コーポレイション 炎症性疾患の処置のための併用療法
WO2001081333A2 (en) * 2000-04-25 2001-11-01 Pharmacia Corporation Regioselective synthesis of 3,4-di(carbocyclyl or heterocyclyl)thiophenes
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US20030087942A1 (en) * 2001-08-31 2003-05-08 Washington University Method for the treatment and prevention of cachexia
JP2005506366A (ja) * 2001-10-25 2005-03-03 ノバルティス アクチエンゲゼルシャフト 選択的シクロオキシゲナーゼ−2阻害剤を含む組合せ剤
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US20070078121A1 (en) 2004-12-23 2007-04-05 Flynn Daniel L Enzyme modulators and treatments
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US20080098491A1 (en) * 2006-10-19 2008-04-24 Zoltan Laboratories Llc Mouse models to study cachexia
EA200970700A1 (ru) 2007-04-20 2010-02-26 ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Ингибиторы киназы, пригодные для лечения миелопролиферативных заболеваний и других пролиферативных заболеваний
AU2008274941A1 (en) * 2007-07-12 2009-01-15 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
CA2700665A1 (en) * 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Combination therapy for the treatment of cancer using cox-2 inhibitors and dual inhibitors of egfr [erbb1] and her-2 [erbb2]
CA2700664A1 (en) * 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and aromatase inhibitors or combinations of cox-2 inhibitors and estrogen receptor antagonists
JP2010540460A (ja) * 2007-09-24 2010-12-24 トラガラ ファーマシューティカルズ,インク. COX‐2阻害薬と抗HER2[ErbB2]抗体の混合物又はCOX‐2阻害薬とHER2[ErbB2]受容体チロシンキナーゼ阻害薬の混合物を用いた癌の治療
US20110301209A1 (en) * 2007-11-28 2011-12-08 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
JP2011506277A (ja) * 2007-11-28 2011-03-03 トラガラ ファーマシューティカルズ,インク. Cox−2阻害薬と代謝拮抗物質との組み合わせを使用する癌治療
MX2011004535A (es) 2008-10-29 2011-11-18 Deciphera Pharmaceuticals Llc Ciclopropanamidas y analogos que exhiben actividades anti-cancer y anti-proliferativas.
EP2284154A1 (en) * 2009-07-29 2011-02-16 Argon Pharma S.L. Antitumor 1,2-diphenylpyrrole compounds and their preparation process
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CN111818915B (zh) 2018-01-31 2024-05-24 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
KR20220045189A (ko) 2019-08-12 2022-04-12 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양을 치료하는 방법
EP4327827A3 (en) 2019-12-30 2024-05-29 Deciphera Pharmaceuticals, LLC Amorphous kinase inhibitor formulations and methods of use thereof
JP2023509628A (ja) 2019-12-30 2023-03-09 デシフェラ・ファーマシューティカルズ,エルエルシー 1-(4-ブロモ-5-(1-エチル-7-(メチルアミノ)-2-オキソ-1,2-ジヒドロ-1,6-ナフチリジン-3-イル)-2-フルオロフェニル)-3-フェニル尿素の組成物
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962119A (en) * 1989-06-09 1990-10-09 Warner-Lambert Company Triazole derivatives of fenamates as antiinflammatory agents
KR920702621A (ko) 1989-06-13 1992-10-06 스튜어트 알. 슈터 단핵세포 및/또는 마크로파지에 의한 인터루킨-1 또는 종양회사인자 생성의 억제
US5504107A (en) 1990-01-12 1996-04-02 The Ohio State University Research Foundation Optically pure 4-alkenyl- or 4-alkanyl-2-hydroxytetronic acids and pharmaceutical use thereof
US5208018A (en) 1990-03-19 1993-05-04 Brigham And Women's Hospital Treatment of cachexia with interleukin 2
WO1992010190A1 (en) 1990-12-13 1992-06-25 Smithkline Beecham Corporation Novel csaids
WO1992010498A1 (en) 1990-12-13 1992-06-25 Smithkline Beecham Corporation Novel csaids
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
DE69406903T2 (de) 1993-01-15 1998-04-09 Searle & Co 3,4-diarylthiophene und analoga davon, sowie deren verwendung als entzündungshemmende mittel
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
ES2155092T3 (es) 1993-07-13 2001-05-01 Janssen Pharmaceutica Nv Imidazoazepinas antialergicas.
US5593991A (en) 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
ATE212985T1 (de) 1993-11-30 2002-02-15 Searle & Co Tricyclische,substituierte pyrazolyl- benzolsulfonamide und ihre verwendung als cyclooxygenase ii inhibitoren
AU1269495A (en) 1994-01-10 1995-08-01 Merck Frosst Canada Inc. Phenyl heterocycles as cox-2 inhibitors
US5418254A (en) 1994-05-04 1995-05-23 G. D. Searle & Co. Substituted cyclopentadienyl compounds for the treatment of inflammation
JP3302178B2 (ja) 1994-06-22 2002-07-15 日本クラウンコルク株式会社 合成樹脂製容器蓋
US5486534A (en) 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
JP2636819B2 (ja) * 1994-12-20 1997-07-30 日本たばこ産業株式会社 オキサゾール系複素環式芳香族化合物
US5593119A (en) * 1995-01-12 1997-01-14 At&T Global Information Solutions Company Apparatus and method for mounting a terminal
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
RU2200158C2 (ru) 1995-02-13 2003-03-10 Джи.Ди.Сирл энд Ко. Замещенные изоксазолы, фармацевтические композиции на их основе и способ подавления воспалений
CA2221692A1 (en) 1995-05-19 1996-11-21 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
EP0828718A1 (en) 1995-06-02 1998-03-18 G.D. SEARLE & CO. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
CA2180624C (en) 1995-07-12 2006-12-12 Cheuk Kun Lau Diphenyl-1,2,3-thiadiazoles as anti-inflammatory agents
GB9520584D0 (en) 1995-10-09 1995-12-13 Fujisawa Pharmaceutical Co Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
ATE236130T1 (de) 1996-01-26 2003-04-15 Searle & Co Heterocyclisch substituierte imidazole zur behandlung von entzündungen
JPH09323930A (ja) * 1996-04-04 1997-12-16 Takeda Chem Ind Ltd 悪液質の予防・治療剤
US5908858A (en) 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
TR199802049T2 (xx) 1996-04-12 1999-01-18 G.D.Searle & Co. COX-2 Inhibit�rlerinin �nilac� olarak s�bstit�e edilmi� benzens�lfonamid t�revleri.
EP1283203A1 (en) * 1996-08-14 2003-02-12 G.D. Searle & Co. Crystalline form of 4-(5-methyl-3-phenylisoxazol-4-yl) benzene-sulfonamide
EP1479385B1 (en) 1996-10-15 2008-07-02 G.D. Searle LLC Use of cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
EP0941080A2 (en) 1996-11-19 1999-09-15 G.D. SEARLE & CO. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
ES2208964T3 (es) 1996-12-10 2004-06-16 G.D. SEARLE & CO. Compuestos de pirrolilo substituidos para el tratamiento de la inflamacion.
EP0863134A1 (en) * 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia

Also Published As

Publication number Publication date
CA2257010C (en) 2009-02-17
HUP9803018A2 (hu) 1999-10-28
HU9803018D0 (en) 1999-02-01
KR100483244B1 (ko) 2005-04-15
NO20040145L (no) 1999-06-25
SA99191102B1 (ar) 2006-10-11
AU745865B2 (en) 2002-04-11
ID21529A (id) 1999-06-24
HU227126B1 (en) 2010-07-28
HK1020261A1 (en) 2000-04-07
EP0927555B1 (en) 2011-10-05
AU9822598A (en) 1999-07-15
US20050004109A1 (en) 2005-01-06
CA2257010A1 (en) 1999-06-24
TW562675B (en) 2003-11-21
TR199802676A2 (xx) 1999-11-22
BR9805544C1 (pt) 2000-06-06
NO986089D0 (no) 1998-12-23
PL193093B1 (pl) 2007-01-31
KR100432926B1 (ko) 2004-09-08
US6887893B1 (en) 2005-05-03
NO320632B1 (no) 2006-01-02
IL127664A0 (en) 1999-10-28
CN1230407A (zh) 1999-10-06
NZ333399A (en) 2000-05-26
IL143921A0 (en) 2002-04-21
US7745481B2 (en) 2010-06-29
HUP9803018A3 (en) 2000-09-28
AR012272A1 (es) 2000-09-27
US20050014814A1 (en) 2005-01-20
BR9805544A (pt) 2000-03-28
NO317568B1 (no) 2004-11-15
CZ299060B6 (cs) 2008-04-16
EP0927555A1 (en) 1999-07-07
CZ425898A3 (cs) 1999-07-14
KR19990063439A (ko) 1999-07-26
NO986089L (no) 1999-06-25
CN1149990C (zh) 2004-05-19
IL127664A (en) 2003-04-10
ES2372921T3 (es) 2012-01-27
KR20040025927A (ko) 2004-03-26
ATE527022T1 (de) 2011-10-15
TR199802676A3 (tr) 1999-11-22
DK0927555T3 (da) 2012-01-23
PL330496A1 (en) 1999-07-05

Similar Documents

Publication Publication Date Title
IL143921A (en) Compositions for the treatment and prevention of tumor-related disorders, for inhibiting tumor growth and for inhibiting tumor metastasis
AU2212299A (en) Compositions and methods for the treatment of tumor
HUP0103856A3 (en) Pharmaceutical composition for the treatment of acute disorders
ZA200109073B (en) Compositions for treatment of disorders of the oesophagus.
HK1027280A1 (en) Plant extracts for the treatment of increased boneresorption.
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2495200A (en) Compositions and methods for the treatment of tumor
KR100510795B1 (en) Compositions and Methods for the Treatment of Tumor
ZA200007642B (en) Treatment of airborne microorganisms.
HK1043019A1 (en) Compositions and methods for prevention and treatment of protozoal disease.
GB9806929D0 (en) MEK inhibiting compounds,compositions containing such compounds and methods of treatment
PH31326A (en) Methods of inhibiting breast disorders.
IL141426A0 (en) Compositions and methods for the treatment of tumor
ZA97252B (en) Compositions for the prevention and treatment of osteoporosis.
IL143212A0 (en) Compositions and methods for the treatment of tumor
HUP0101947A3 (en) Combination for the treatment of tumors
ZA9811840B (en) Methods and compositions for the treatment and prevention of tumors tumor-related disorders and cachexia
ZA99253B (en) Treatment of waxes.
GB9814269D0 (en) 9a-Aza-3-ketolides, compositions containing such compounds and methods of treatment
AP2005003432A0 (en) Novel method of treatment.
KR100511819B1 (en) Compositions and Methods for the Treatment of Tumor
ZA988293B (en) Compositions and methods for the treatment of tumor.
AU2224800A (en) Compositions and methods for the treatment of tumor

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees